A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
This study is a single-center, open-label, 3-group, fixed-sequence drug-drug interaction
 study to assess the effect of coadministration of multiple-dose itraconazole or diltiazem on
 the single-dose PK of AZD3293 and the effects of coadministration of single- and
 multiple-dose AZD3293 on the single-dose PK of midazolam. The study will also evaluate the
 safety and tolerability of single and multiple oral doses of AZD3293, alone and in
 combination with itraconazole, diltiazem, and midazolam in healthy young subjects.AZD3293 is
 being developed for the treatment of Alzheimer's disease
Inclusion Criteria:

 -  Provision of signed, written, and dated informed consent prior to any study-specific
 procedures Male and nonfertile female healthy subjects, aged 18 to 55 years at the
 time of consent

 -  Body weight ≥50 to ≤100 kg and body mass index (BMI) ≥19 to ≤30 kg/m2

 -  Clinically normal findings on physical examination in relation to age, as judged by
 the Investigator

 -  Male healthy subjects must be willing to use barrier contraception, ie, condoms, even
 if their partners are post-menopausal, surgically sterile, or using accepted
 contraceptive methods, from the first day of dosing until 3 months after the last dose
 of investigational product (IP)

 Exclusion Criteria:

 -  Participation in any prior study of AZD3293

 -  History of any clinically significant disease or disorder which, in the opinion of the
 Investigator, may put the subject at risk because of participation in the study, may
 influence the results, or may limit the subject's ability to participate in the study

 -  History or presence of gastrointestinal, hepatic or renal disease or any other
 condition known to interfere with absorption, distribution, metabolism or excretion of
 drugs

 -  History of previous or ongoing psychiatric disease/condition including psychosis,
 affective disorder, anxiety disorder, borderline state and personality disorder
 according to the criteria in the Diagnostic and Statistical Manual of Mental
 Disorders, 4th edition (DSM IV), as assessed by the Mini-International
 Neuropsychiatric Interview (MINI)